Nonalcoholic fatty liver disease is associated with insulin resistance in a young Hispanic population

Preventive Medicine

Volumn 52, Issue 2, 2011, Pages 174-177

  Perez, M ^a   Gonzales L ^a   Olarte, R ^a   Rodriguez N I ^b   Tabares, M ^b   Salazar, J P ^b   Jaimes, S ^b   Garcia R G ^c,d   Lopez Jaramillo P ^c,e  

^a UNIVERSIDAD MILITAR NUEVA GRANADA   (Colombia)

^b Escuela de Posgrados de la Fuerza Aérea Colombiana   (Colombia)

^c UNIVERSIDAD DE SANTANDER   (Colombia)

^d FUNDACIÓN CARDIOVASCULAR DE COLOMBIA   (Colombia)

^e Research Institute of the Fundacion Oftalmologica de Santander FOSCAL   (Colombia)

Author keywords

Fatty liver disease; Hispanic population; Insulin resistance; Metabolic syndrome

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL; URIC ACID;

ADULT; AIR FORCE; ANTHROPOMETRY; ARTICLE; BIOCHEMISTRY; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; COLOMBIA; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HISPANIC; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PREDICTOR VARIABLE; PRIORITY JOURNAL; SUBCUTANEOUS FAT;

ADULT; AGE DISTRIBUTION; ANTHROPOMETRY; BODY MASS INDEX; COLOMBIA; COMORBIDITY; CROSS-SECTIONAL STUDIES; FATTY LIVER; HISPANIC AMERICANS; HUMANS; INSULIN RESISTANCE; LIVER FUNCTION TESTS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 78751702116     PISSN: 00917435     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ypmed.2010.11.021     Document Type: Article

References (32)

1. Alberti K.G., Zimmet P., Shaw J. The metabolic a new worldwide definition. Lancet 2005, 366:1059-1062. IDF Epidemiology Task Force Consensus Group.
2. Angulo P., Keach J.C., Batts K.P., Lindor K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30:1356-1362.
3. Angulo P. Non alcoholic fatty liver disease. Rev. Gastroenterol. Méx. 2005, 70(S3):52-56.
4. Bacon B.R., Farahvash M.J., Janney C.G., Neuschwander-Tetri B.A. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994, 107:1103-1109.
5. Browning J.D., Sczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
6. Bugianesi E., Zannoni C., Vanni E., Marzocchi R., Marchesini G. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship?. Dig. Liver Dis. 2004, 36:165-173.
7. Bugianesi E., Gastaldelli A., Vanni E., et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005, 48:634-642.
8. Comert B., Mas M.R., Erdem H., et al. Insulin resistance in non-alcoholic steatohepatitis. Dig. Liver Dis. 2001, 33:353-358.
9. Coutinho M., Gerstein H.C., Wang Y., Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diab. Care 1999, 22:233-240.
10. Csendes P., Paolinelli P., Busel D., Venturelli V., Rodríguez J. Hígado graso: Ultrasonido y correlación anatomo-patológica. Rev. Chil. Radiol. 2004, 10:50-52.
11. Deivanayagam S., Mohammed B.S., Vitola B.E., et al. Nonalcoholic fatty liver disease is associated with hepatic and skeletal muscle insulin resistance in overweight adolescents. Am. J. Clin. Nutr. 2008, 88:257-262.
12. Falck-Ytter Y., Younossi Z.M., Marchesini G., McCullough A.J. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin. Liver Dis. 2001, 21:17-26.
13. Garcia R.G., Cifuentes A.E., Caballero R.S., Sanchez L., López-Jaramillo P. A proposal for an appropriate central obesity diagnosis in Latin American population. Int. J. Cardiol. 2006, 110:263-264.
14. Garcia R.G., Perez M., Maas R., Schwedhelm E., Böger R.H., López-Jaramillo P. Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. Int. J. Cardiol. 2007, 122:176-178.
15. Harrison S.A., Neuschwander-Tetri B.A. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin. Liver Dis. 2004, 8:861-879.
16. Lin H.Z., Yang S.Q., Chuckaree C., Kuhajda F., Ronnet G., Diehl A.M. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med. 2000, 6:998-1003.
17. Lohman T., Roche A., Martorel R. Standardization of anthropometric measurements. The airle (VA) consensus conference. Hum. Kinet. 1988, 11:39-80.
18. Lopez-Jaramillo P., Silva S.Y., Rodriguez-Salamanca N., Duran A., Mosquera W., Castillo V. Are nutrition-induced epigenetic changes the link between socioeconomic pathology and cardiovascular diseases?. Am. J. Ther. 2008, 15:362-372.
19. Lopez-Jaramillo P. Cardio metabolic diseases in Latin America: the role of fetal programming in response to maternal malnutrition. Rev. Esp. Cardiol. 2009, 62:670-676.
20. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
21. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Zoli M., Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001, 358:893-894.
22. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Oliver D., Bacon B.R. Improved nonalcoholic steatohepatitis after 48weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003, 38:1008-1017.
23. O'Brien E., Asmar R., Beilin L., et al. European society of hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J. Hypertens. 2003, 21:821-848.
24. Park S.H., Kim B.I., Kim S.H., et al. Body fat distribution and insulin resistance: beyond obesity in nonalcoholic fatty liver disease among overweight men. J. Am. Coll. Nutr. 2007, 26:321-326.
25. Ribeiro-Filho F., Faria A.N., Azjen S., Zanella M.T., Ferreira S.R. Methods of estimation of visceral fat: advantages of ultrasonography. Obes. Res. 2003, 11:1488-1494.
26. Saadeh S., Younossi Z.M., Remer E.M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123:745-750.
27. Sanyal A.J., Campbell-Sargent C., Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.
28. Selvin E., Steffes M.W., Zhu H., et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N. Engl. J. Med. 2010, 362:800-811.
29. Seppala-Lindroos A., Vehkavaara S., Hakkinen A.M., et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal me. J. Clin. Endocrinol. Metab. 2002, 87:3023-3028.
30. Sobhonsldsuk A., Jongjirasiri S., Thakkinstian A., Wisedopas N., Bunnag P., Puavilai G. Visceral fat and insulin resistance as predictors of non-alcoholic steatohepatitis. World J. Gastroenterol. 2007, 13:3614-3618.
31. Targher G., Bertolini L., Padovani R., et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diab. Care 2007, 30:1212-1218.
32. Utzschneider K.M., Kahn S.E. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 2006, 91:4753-4761.